Streetbeat News

Regulatory

BMY

Bristol Myers Squibb (NYSE:BMY) announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, demonstrating long-term survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer. The results will be presented at the IASLC 2023 World Conference on Lung Cancer.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 11:00 am

FREY

FREYR Battery (NYSE:FREY), a developer of clean, next-generation battery cell production capacity, has announced that its US affiliate, FREYR Battery, Inc., has filed an S-4 registration statement with the SEC. This is part of its previously announced plan to redomicile from Luxembourg to the US by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 10:02 am

CING

Cingulate Inc. (NASDAQ:CING) announced full results from the Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301 (dexmethylphenidate), for the treatment of ADHD. The study did not achieve statistical significance on the primary efficacy endpoint but demonstrated a trend toward significance in improving PERMP scores with CTx-1301 compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 10:01 am

SVA

Sinovac Biotech Ltd. (NASDAQ:SVA) has completed the phase I clinical trial for its Anti-COVID-19 Antibody SA55 Injection in Beijing and has begun the phase II clinical trial in Shanghai. The phase I trial confirmed the preliminary safety profile of the SA55 Injection in 40 healthy adults. The phase II trial will enroll 150 patients with mild to moderate COVID-19 infection to evaluate the drug's ability to decrease virus loads and alleviate symptoms.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 9:58 am

FXI

China is planning to increase scrutiny of local government financial vehicles as part of a rescue package, according to Reuters. This move could potentially impact the financial stability of local governments and their ability to raise funds.

Portfolio Pulse from Charles Gross

September 11, 2023 | 9:52 am

VGK

The EU has forecasted that the Eurozone is likely to grow at a slower pace in 2023 and 2024 due to weak domestic consumption and global demand.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 9:30 am

FXI

China's foreign exchange self-regulatory body has stated that the Yuan exchange rate has a solid basis to remain reasonably stable at reasonable and balanced levels, according to a statement from the China Central Bank.

Portfolio Pulse from Charles Gross

September 11, 2023 | 9:28 am

FXI

SPY

China's Central Bank is set to acquire approval for bulk dollar buying of $50M and above. This move could potentially impact the value of the dollar and related ETFs.

Portfolio Pulse from Charles Gross

September 11, 2023 | 9:02 am

AZN

AstraZeneca and Daiichi Sankyo's drug ENHERTU showed strong and durable tumor responses in previously treated patients with HER2 mutant advanced lung cancer in the DESTINY-Lung02 phase 2 trial. The results were presented at the IASLC 2023 World Conference on Lung Cancer and published in the Journal of Clinical Oncology.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:46 am

NONOF

The family of a man who committed suicide is seeking a warning label on the weight loss drug Ozempic, claiming it contributed to his death. The man's mood changes were linked to his use of the Type 2 diabetes medicine. The FDA and the drug’s manufacturer, Novo Nordisk (OTC:NONOF), are monitoring the safety of the drug and will take appropriate actions if a new safety signal for suicidal ideation/behavior is identified.

Portfolio Pulse from Benzinga Neuro

September 11, 2023 | 8:40 am